A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)
Ralph V. Boccia(Center for Cancer and Blood Disorders), James R. Berenson(Oncotherapeutics (United States)), Amy Kimball(University of Maryland, Baltimore), Dawn Pinchasik(Amgen (United States)), Richy Agajanian(Oncology Institute of Hope and Innovation), Paul Conkling(Virginia Oncology Associates), Alberto Bessudo(California Cancer Associates for Research and Excellence), Wael A. Harb, Hui Yang(Amgen (United States))
Cited by 19
Related Papers
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Assessment of thymic output in adults after haematopoietic stemcell transplantation and prediction of T-cell reconstitution
|The Lancet|2000|579
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425